专利检索 ap:("AbbVie S.À.R.L." OR "Galapagos NV") AND inv:"BOGDAN, Andrew" 第 1 页

1.

发明公开
HETEROARYL SUBSTITUTED PYRIDINES AND METHODS OF USE 审中-公开

公开(公告)号：EP3464282A1

公开(公告)日：2019-04-10

申请号：EP17728272.0

申请日：2017-05-24

申请人： AbbVie S.À.R.L. , Galapagos NV

发明人： ALTENBACH, Robert J. , BOGDAN, Andrew , COTI, Ghjuvanni Petru Diunisu , COWART, Marlon D. , GRESZLER, Stephen N , KELGTERMANS, Hans , KYM, Philip R. , VAN DER PLAS, Steven Emiel , WANG, Xueqing

IPC分类号： C07D413/14 , C07D413/04 , C07D417/04 , C07D417/14 , A61K31/4439 , A61P11/00

摘要： wherein X1, X2, R1, and R2 are as defined herein. The present invention relates to compounds and their use in the treatment of cystic fibrosis, methods for their production, pharmaceutical compositions comprising the same, and methods of treating cystic fibrosis by administering a compound of the invention.

2.

发明公开
MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR PROTEIN 审中-公开

公开(公告)号：EP3448842A1

公开(公告)日：2019-03-06

申请号：EP17722167.8

申请日：2017-04-24

申请人： AbbVie S.À.R.L. , Galapagos NV

发明人： ALTENBACH, Robert J. , BOGDAN, Andrew , CHAN, Vincent , GRIEME, Timothy A. , KOENIG, John R. , KYM, Philip R. , LIU, Bo , MALAGU, Karine Fabienne , PATEL, Sachin V. , SCANIO, Marc , SEARLE, Xenia B. , SHEKHAR, Shashank , WANG, Xueqing , YEUNG, Ming C.

IPC分类号： C07D311/58 , A61K31/352 , C07D311/60 , C07D407/12 , C07D407/14 , A61P11/00

3.

发明公开
SUBSTITUTED CHROMANES AND METHOD OF USE 审中-公开
标题翻译：取代的色谱和使用方法

公开(公告)号：EP3212189A1

公开(公告)日：2017-09-06

申请号：EP15854320.7

申请日：2015-10-28

申请人： AbbVie S.À.R.L. , Galapagos NV

发明人： KYM, Philip R. , WANG, Xueqing , SEARLE, Xenia B. , LIU, Bo , YEUNG, Ming C. , ALTENBACH, Robert J. , VOIGHT, Eric , BOGDAN, Andrew , KOENIG, John R.

IPC分类号： A61K31/44 , C07D471/04 , C07D311/58

摘要： The invention provides for compounds of formula (I) wherein R1, X, Y, R4, R5, R6, R7, R8, R9, R10, R11, R12, R13, R14, m, and R″ have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions mediated and modulated by CFTR, including cystic fibrosis, Sjögren's syndrome, pancreatic insufficiency, chronic obstructive lung disease, and chronic obstructive airway disease. Also provided are pharmaceutical compositions comprised of one or more compounds of formula (I).

摘要翻译： 其中R1，X，Y，R4，R5，R6，R7，R8，R9，R10，R11，R12，R13，R14，m和R“具有本说明书中所定义的任何值及其药学上可接受的盐，它们可用作治疗由CFTR介导和调节的疾病和病症的药物，包括囊性纤维化，斯耶格伦综合征，胰腺功能不全，慢性阻塞性肺病和慢性阻塞性气道疾病。还提供了由一种或多种式（I）化合物组成的药物组合物。

4.

发明授权
MODULATORS OF THE CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR PROTEIN AND METHODS OF USE 有权

公开(公告)号：EP3681864B1

公开(公告)日：2020-10-28

申请号：EP18779798.0

申请日：2018-09-13

申请人： AbbVie Overseas S.à r.l. , Galapagos NV

发明人： ALTENBACH, Robert J. , BOGDAN, Andrew , COUTY, Sylvain , DESROY, Nicolas , GFESSER, Gregory A. , HOUSSEMAN, Christopher Gaëtan , KYM, Philip R. , LIU, Bo , MAI, Thi Thu Trang , MALAGU, Karine Fabienne , MERAYO MERAYO, Nuria , PICOLET, Olivier Laurent , PIZZONERO, Mathieu Rafaël , SEARLE, Xenia B. , VAN DER PLAS, Steven Emiel , WANG, Xueqing , YEUNG, Ming C.

IPC分类号： C07D213/71 , C07D215/36 , C07D231/56 , C07D401/12 , C07D235/28 , C07D471/04 , C07D213/64 , C07C311/45 , A61P11/00 , A61K31/4709

5.

发明公开
SUBSTITUTED PYRROLIDINES AS CFTR MODULATORS 审中-公开

公开(公告)号：EP3523277A1

公开(公告)日：2019-08-14

申请号：EP17794414.7

申请日：2017-10-04

申请人： Abbvie S.a.r.l. , Galapagos NV

发明人： ALTENBACH, Robert J. , BOGDAN, Andrew , DESROY, Nicolas , GFESSER, Gregory A. , GRESZLER, Stephen N. , KOENIG, John R. , KYM, Philip R. , LIU, Bo , SCANIO, Marc J. , SEARLE, Xenia , WANG, Xueqing , YEUNG, Ming C. , ZHAO, Gang

IPC分类号： C07D207/16 , C07D401/12 , A61K31/4025 , A61K31/4439 , A61P11/00

6.

发明公开
MODULATORS OF THE CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR PROTEIN AND METHODS OF USE 审中-公开

公开(公告)号：EP3681864A1

公开(公告)日：2020-07-22

申请号：EP18779798.0

申请日：2018-09-13

申请人： AbbVie Overseas S.à r.l. , Galapagos NV

发明人： ALTENBACH, Robert J. , BOGDAN, Andrew , COUTY, Sylvain , DESROY, Nicolas , GFESSER, Gregory A. , HOUSSEMAN, Christopher Gaëtan , KYM, Philip R. , LIU, Bo , MAI, Thi Thu Trang , MALAGU, Karine Fabienne , MERAYO MERAYO, Nuria , PICOLET, Olivier Laurent , PIZZONERO, Mathieu Rafaël , SEARLE, Xenia B. , VAN DER PLAS, Steven Emiel , WANG, Xueqing , YEUNG, Ming C.

IPC分类号： C07D213/71 , C07D215/36 , C07D231/56 , C07D401/12 , C07D235/28 , C07D471/04 , C07D213/64 , C07C311/45 , A61P11/00 , A61K31/4709

7.

发明公开
SUBSTITUTED TRICYCLICS AND METHOD OF USE 审中-公开

公开(公告)号：EP3322697A1

公开(公告)日：2018-05-23

申请号：EP16739584.7

申请日：2016-07-14

申请人： Abbvie S.a.r.l. , Galapagos NV

发明人： ALTENBACH, Robert J. , BOGDAN, Andrew , COWART, Marlon D. , ESMIEU, William Ramesh , GFESSER, Gregory A. , GRESZLER, Stephen N. , KOENIG, John R. , KYM, Philip R. , LIU, Bo , MALAGU, Karine Fabienne , PATEL, Sachin V. , SCANIO, Marc J. , SEARLE, Xenia B. , VOIGHT, Eric , WANG, Xueqing , YEUNG, Ming C.

IPC分类号： C07D317/70 , C07D405/12 , C07D407/12 , C07D493/04 , C07D519/00 , A61K31/36 , A61K31/404 , A61K31/426 , A61K31/433 , A61K31/443 , A61K31/4184 , A61K31/501 , A61K31/497 , A61P11/00

摘要： wherein X, Y, and R1 have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions mediated and modulated by CFTR, including cystic fibrosis, Sjögren's syndrome, pancreatic insufficiency, chronic obstructive lung disease, and chronic obstructive airway disease. Also provided are pharmaceutical compositions comprised of one or more compounds of formula (I).